50 completed. 50 Phase 2, 6 Phase 1, 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 50 | Completed 50 |
| Phase 1 | 6 | Completed 6 |
| Phase 3 | 6 | Completed 6 |
Follow Cholestasis: new trials by email Literature Review of Cholestasis trials Research Report on Cholestasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment. K-808 (Dose A), K-808 (Dose B), Placebo - Primary Biliary Cholangitis | Phase 2 | Completed | Kowa Research Institute, Inc. | 46 | 2024-02-07 | 2026-10-07 |
| Comparative Study of REMAXA®, Enteric-coated Tablets and REMAXOL®, Solution for Infusions, in Intrahepatic Cholestasis Remaxa, enteric-coated tablets, Remaxol, Placebo - Cholestasis, Intrahepatic | Phase 2 / Phase 3 | Completed | POLYSAN Scientific & Technological Pharmaceutical Company | 328 | 2023-05-27 | 2025-04-29 |
| A Two-part Study to Investigate the Effects in Adults of Two Doses of Golexanolone in Patients With Primary Biliary Cholangitis (PBC) With Fatigue and Cognitive Dysfunction golexanolone, Placebo - Primary Biliary Cholangitis (PBC) | Phase 1 / Phase 2 | Completed | Umecrine Cognition AB | 207 | 2023-04-14 | 2026-10-16 |
| Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis EP547, Placebo - Pruritus | Phase 2 | Completed | Escient Pharmaceuticals, Inc | 62 | 2022-10-06 | 2025-07-31 |
| Study to Evaluate the Safety and Efficacy of ASC42 Tablets in Subjects With Primary Biliary Cholangitis ASC42 5 mg, ASC42 10 mg, ASC42 15 mg - Primary Biliary Cholangitis | Phase 2 | Completed | Gannex Pharma Co., Ltd. | 98 | 2022-04-06 | 2024-09-27 |
| Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Placebo - Primary Biliary Cholangitis | Phase 2 / Phase 3 | Completed | Zydus Therapeutics Inc. | 196 | 2022-04-01 | 2026-09-17 |
| Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC Bezafibrate 100 mg, Bezafibrate 200 mg, Obeticholic Acid 5 mg - Primary Biliary Cholangitis | Phase 2 | Completed | Intercept Pharmaceuticals | 72 | 2022-03-21 | 2026-07-16 |
| A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness Setanaxib, Placebo - Primary Biliary Cholangitis, Liver Stiffness | Phase 2 | Completed | Calliditas Therapeutics Suisse SA | 76 | 2022-02-14 | 2025-04-24 |
| Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis CNP-104, Placebo - Primary Biliary Cholangitis | Phase 1 / Phase 2 | Completed | COUR Pharmaceutical Development Company, Inc. | 42 | 2022-01-25 | 2026-03-10 |
| A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS). Maralixibat - Progressive Familial Intrahepatic Cholestasis, Alagille Syndrome | Phase 2 | Completed | Mirum Pharmaceuticals, Inc. | 27 | 2021-09-09 | 2026-06-02 |
| Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis HTD1801 (BUDCA) - Primary Biliary Cholangitis, Primary Biliary Cirrhosis | Phase 2 | Completed | HighTide Therapeutics (Hong Kong) Limited | 24 | 2021-05-27 | 2026-08-25 |
| Combination Antiretroviral Therapy (cART) for PBC Emtricitabine (FTC)/Tenofovir Disoproxil (TDF), Raltegravir, Placebo Oral Capsule [CEBOCAP] - Primary Biliary Cholangitis | Phase 2 | Completed | University of Alberta | 37 | 2021-03-01 | 2024-02-16 |
| Umbilical Cord Derived Mesenchymal Stem Cell (UC -MSC) Transplantation for Children Suffering From Biliary Atresia Umbilical Cord Derived Mesenchymal Stem Cell (UC -MSC) Transplantation - Primary Biliary Cirrhosis | Phase 1 / Phase 2 | Completed | Vinmec Research Institute of Stem Cell and Gene Technology | 20 | 2019-08-10 | 2024-06-06 |
| Needle-Knife Fistulotomy Vs. Standard Cannulation Trial Needle Knife Fistulotomy, standard biliary cannulation - Biliary Obstruction Due to Common Bile Duct Stone, Malignant Bile Duct Obstruction | Phase 1 / Phase 2 | Completed | Thomas Jefferson University | 186 | 2019-01-31 | 2024-11-19 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis EDP-305 1 mg, EDP-305 2.5 mg, Placebo - Primary Biliary Cholangitis | Phase 2 | Completed | Enanta Pharmaceuticals, Inc | 68 | 2017-12-27 | 2021-05-18 |
| Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary Cholangitis Saroglitazar magnesium 2 mg, Saroglitazar magnesium 4 mg, Placebo Oral Tablet - Primary Biliary Cirrhosis | Phase 2 | Completed | Zydus Therapeutics Inc. | 37 | 2017-08-18 | 2024-09-19 |
| Study to Assess Safety & Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodiol. GKT137831, Placebo oral capsule - Primary Biliary Cirrhosis | Phase 2 | Completed | Calliditas Therapeutics AB | 111 | 2017-06-26 | 2022-06-29 |
| Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid Elafibranor 80 mg, Elafibranor 120 mg, Placebo - Primary Biliary Cholangitis (PBC) | Phase 2 | Completed | Genfit | 45 | 2017-04-05 | 2019-09-24 |
| Dose Response Study of GSK2330672 for the Treatment of Pruritus in Participants With Primary Biliary Cholangitis Placebo, GSK2330672 - Cholestasis | Phase 2 | Completed | GlaxoSmithKline | 147 | 2017-01-11 | 2021-05-04 |
| Autologous Bone Marrow Mononuclear Stem Cell for Children Suffering From Liver Cirrhosis Due to Biliary Atresia Autologous BMMC transplantation - Liver Cirrhosis, Biliary | Phase 2 | Completed | Vinmec Research Institute of Stem Cell and Gene Technology | 17 | 2017-01-02 | 2024-06-04 |
Showing 20 of 50. Sign in to see all of them.
Liver Cirrhosis, Biliary (33) · Alagille Syndrome (6) · Pruritus (5) · Cholestasis, Intrahepatic (3) · Short Bowel Syndrome (3) · Bile Duct Diseases (2) · Biliary Atresia (2) · Biliary Tract Diseases (2) · Cholangitis (2) · Cholestasis, progressive familial intrahepatic 1 (2) · Fatigue (2) · Liver Cirrhosis (2) · Liver Diseases (2) · Carcinoma, Hepatocellular (1)
Digestive System Diseases (50) · Bile Duct Diseases (48) · Biliary Tract Diseases (48) · Liver Diseases (41) · Pathological Conditions, Signs and Symptoms (40) · Cholestasis, Intrahepatic (38) · Pathologic Processes (38) · Fibrosis (32) · Liver Cirrhosis (31) · Congenital Abnormalities (9) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (9) · Signs and Symptoms (9) · Abnormalities, Multiple (6) · Cardiovascular Abnormalities (6)
fish oil triglycerides (5) · maralixibat (5) · Ursodeoxycholic Acid (3) · obeticholic acid (3) · 3-((((3R,5R)-3-butyl-3-ethyl-7-(methyloxy)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepin-8-yl)methyl)amino)pentanedioic acid (2) · Rituximab (2) · aldafermin (2) · saroglitazar (2) · setanaxib (2) · (2-methyl-4-(5-methyl-2-(4-trifluoromethyl-phenyl)-2H-(1,2,3)triazol-4-ylmethylsulfanyl)phenoxy)acetic acid (1) · (R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acid (1) · 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid (1) · 3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid (1) · Bezafibrate (1) · Ceftriaxone (1)
Mirum Pharmaceuticals, Inc. (8) · Intercept Pharmaceuticals (3) · GlaxoSmithKline (2) · NGM Biopharmaceuticals, Inc (2) · University of Alberta (2) · Vinmec Research Institute of Stem Cell and Gene Technology (2) · Zydus Therapeutics Inc. (2) · Arthur J De Lorimier (1) · COUR Pharmaceutical Development Company, Inc. (1) · Calliditas Therapeutics AB (1) · Calliditas Therapeutics Suisse SA (1) · Conatus Pharmaceuticals Inc. (1) · Enanta Pharmaceuticals, Inc (1) · Escient Pharmaceuticals, Inc (1) · Gannex Pharma Co., Ltd. (1)
United States (37) · United Kingdom (19) · Canada (17) · Germany (10) · France (9) · Spain (9) · Australia (6) · Belgium (6) · Poland (6) · Italy (5) · Austria (3) · Greece (3) · Israel (3) · Argentina (2) · Hungary (2)
Liem Nguyen (2) · Stephen J Rossi, PharmD (2) · Adrian DiBisceglie, MD (1) · Andre Belous, MD, PhD (1) · Andrew L Mason, MBBS MRCPI (1) · Andrew Mason, MD (1) · Bruce Bacon, MD (1) · Catherine Vincent, MD FRCPC (1) · Christian Weyer, MD (1) · Christopher Bowlus, MD (1) · Christopher L Bowlus, MD (1) · Claudia O. Zein, MD, MSc (1)
PMID 42002216, PMID 38780109, PMID 19661785, PMID 21083674, PMID 23201707, PMID 25543678, PMID 27431238, PMID 28187915, PMID 29790196, PMID 32059815, PMID 33038344, PMID 33484775, PMID 33769355, PMID 34487750, PMID 34695449, PMID 34755627, PMID 35287722, PMID 35367282, PMID 35507739, PMID 36096175, PMID 36267872, PMID 36343847, PMID 36809195, PMID 36852705, PMID 37183520, PMID 37953500, PMID 38862718, PMID 39969430, PMID 40439725, PMID 40745549, PMID 40907882
2016 (3), 2015 (1)